Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 Biomarker disease BEFREE Because it has been reported that high-expression and/or overactivation of VIPR2 link to schizophrenic symptoms, VIPR2 antagonists could be good drug candidates for schizophrenia therapeutics. 30077368 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 GeneticVariation disease BEFREE Furthermore, the 'CC' genotype of the VIPR2 gene was nominally associated with an increased risk of SCZ in male patients. 27156032 2016
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 GeneticVariation disease BEFREE Thus, our results suggest that carriers of microduplication genotypes of VIPR2 are predisposed to SCZ in Han Chinese. 24794882 2014
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 GeneticVariation disease BEFREE For example, a duplication of chromosome 7q36.3 (encoding the VPAC2 receptor) was shown to be associated with schizophrenia, and high levels of PACAP-PAC1 signaling are associated with posttraumatic stress disorder. 24220567 2013
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 Biomarker disease BEFREE We identified a novel duplication within the region associated with schizophrenia identified on 7q36.3 that is adjacent to VIPR2 and is not associated with schizophrenia. 24002029 2013
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 Biomarker disease BEFREE In genome-wide studies of several thousand patients, a significant association of rare microduplications with variable size, all involving VIPR2, with schizophrenia was recently described, suggesting that altered vasoactive intestinal peptide signaling is likely implicated in the pathogenesis of schizophrenia. 23073313 2013
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 Biomarker disease BEFREE These findings implicate altered vasoactive intestinal peptide signalling in the pathogenesis of schizophrenia and indicate the VPAC2 receptor as a potential target for the development of new antipsychotic drugs. 21346763 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 GeneticVariation disease BEFREE Detailed analysis of microduplications at 7q36.3 revealed that the neuropeptide receptor gene VIPR2 confers a significant risk for schizophrenia. 21721910 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 GeneticVariation disease BEFREE Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. 21285140 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.390 Biomarker disease CTD_human Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. 21285140 2011
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.300 Biomarker disease PSYGENET We examined 209 single-nucleotide polymorphisms (SNPs) covering 19 circadian genes (ADCYAP1, ARNTL, ARNTL2, BHLHB2, BHLHB3, CLOCK, CRY1, CRY2, CSNK1E, DBP, NPAS2, NR1D1, PER1, PER2, PER3, RORA, TIMELESS, VIP, and VIPR2) in a sample of 534 MD patients (335 with unipolar major mood depression (MDD) and 199 with bipolar disorder (BD)) and 440 community-based screened controls. 20072116 2010
CUI: C0154778
Disease: Myopia, Degenerative
Myopia, Degenerative 		0.100 GeneticVariation disease GWASCAT A genome-wide meta-analysis identifies two novel loci associated with high myopia in the Han Chinese population. 23406873 2013
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.030 AlteredExpression disease BEFREE Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. 31619964 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 Biomarker group BEFREE These data suggest that VIPR2, which is a negative regulator of smooth muscle cell proliferation, might be a novel tumor suppressor gene in uLMS. 29063609 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.030 AlteredExpression disease BEFREE VIP, VIPR1, and VIPR2 mRNA expression was significantly reduced in PD/CC vs CC and controls (P<.05). 27891695 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.030 Biomarker disease BEFREE Vasoactive intestinal peptide receptor 2 can elicit immune transformation in a model of Parkinson's disease (PD). 26674871 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 AlteredExpression group BEFREE The aim of the present study was to investigate by RT-PCR the mRNA expression of the VPAC1 and VPAC2 receptors in surgical specimens of 43 human lung cancer specimens and 7 normal lung samples. mRNA expression of the VPAC1 receptor was detected in 51% of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46%. 21769421 2011
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.030 Biomarker disease BEFREE Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. 21769421 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.030 Biomarker disease BEFREE Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. 21769421 2011
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.030 Biomarker disease BEFREE Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. 21769421 2011
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.030 AlteredExpression disease BEFREE Results from RT-PCR and immunoblot experiments showed the expression of VPAC(1)-, VPAC(2)- and PAC(1)-R in lung cancer samples. 12732341 2003
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.030 AlteredExpression disease BEFREE Results from RT-PCR and immunoblot experiments showed the expression of VPAC(1)-, VPAC(2)- and PAC(1)-R in lung cancer samples. 12732341 2003
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.030 AlteredExpression disease BEFREE Results from RT-PCR and immunoblot experiments showed the expression of VPAC(1)-, VPAC(2)- and PAC(1)-R in lung cancer samples. 12732341 2003
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.030 AlteredExpression disease BEFREE Although mRNA for VPAC2-R is not common, VPAC1-R and PAC1-R mRNA is present in many lung cancer cell lines. 11193832 2000
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.030 AlteredExpression disease BEFREE Although mRNA for VPAC2-R is not common, VPAC1-R and PAC1-R mRNA is present in many lung cancer cell lines. 11193832 2000